healthy individuals without diseases, inflammatory bowel disease, diabetes, non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, inflammatory bowel disease, irritable bowel syndrome, neuroimmune diseases, patients with carcinoma using immune checkpoint inhibitors for treatment, colorectal cancer, and the elderly.
Conditions
Interventions
None listed
Sponsors
Department for Medical Innovation and Translational Medical Science, Kyoto Prefectural University of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: In 16 clinical studies conducted in the past (see below for details), subjects who have given permission for secondary use at the time of obtaining consent will be subjected to an integrated analysis using already analyzed and anonymized gut microbiota analysis data and subject background factors, after obtaining permission in an information disclosure document (with opt-out). Analysis will be carried out using the already analyzed and anonymized gut microbiota analysis data and subject background factors. The selection criteria will be healthy subjects or patients who are eligible for the above study.
Exclusion criteria
Exclusion criteria: If the research subject is disclosed information about this research and expresses his or her refusal to participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Development of an automatic bacterial flora evaluation program based on the indices obtained from comprehensive integrated analysis | — |
Countries
Japan
Contacts
Public ContactKazuhiko Uchiyama
Kyoto Prefectural University of Medicine Molecular Gastroenterology and Hepatology
Outcome results
None listed